AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34930871 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric nutrition with high protein
Number of subjects: 0
Study 34930871 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased protein intake
Number of subjects: 0
Study 34930871 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 0
Study 34930928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (three batches) administered as dose 1, followed by MVA-BN-Filo (one batch) as dose 2
Number of subjects: 0
Study 34930928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (intermediate dose: 2×10^11 viral particles)
Number of subjects: 0
Study 34930928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (different dose levels)
Number of subjects: 0
Study 34930928 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo (as dose 2)
Number of subjects: 0
Study 34931202 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CCP) high titer (≥1:320)
Number of subjects: 168
Study 34931202 — intervention group
Group type: COMPARATOR
Intervention: Control plasma
Number of subjects: 168
Study 34931603 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment for 3 months
Number of subjects: 259
Study 34931603 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment
Number of subjects: 259
Study 34931696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice (DA)
Number of subjects: 10284
Study 34931696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice (DA) plus oral nutritional supplements (ONS)
Number of subjects: 10284
Study 34931696 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice (DA) plus ONS
Number of subjects: 10284
Study 34931696 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice (DA) versus ONS
Number of subjects: 10284
Study 34931696 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice (DA) versus DA plus ONS
Number of subjects: 10284
Study 34931696 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice (DA) plus ONS versus no advice or ONS
Number of subjects: 10284
Study 34931880 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different immunoglobulin administration modalities
Number of subjects: 0
Study 34931986 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 320
Study 34931986 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 320
Study 34931994 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate consumption of lean red meat 3 times per week for 10 weeks
Number of subjects: 80
Study 34931994 — intervention group
Group type: COMPARATOR
Intervention: Meat alternatives 3 times per week for 10 weeks
Number of subjects: 80
Study 34931994 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires assessing well-being and mental health every 2 weeks
Number of subjects: 80
Study 34931994 — intervention group
Group type: EXPERIMENTAL
Intervention: Body composition, physical function, and blood parameters assessed at allocation
Number of subjects: 80
Study 34932001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological recognition survey completed by community pharmacies (CPs)
Number of subjects: 134
Study 34932001 — intervention group
Group type: EXPERIMENTAL
Intervention: New integrated IT platform for medication reconciliation
Number of subjects: 134
Study 34932005 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted version of the active app with insightful notifications, progress visualization, and access to researcher contact details
Number of subjects: 140
Study 34932005 — intervention group
Group type: COMPARATOR
Intervention: Active app as usual
Number of subjects: 140
Study 34932165 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular CMR-FT analysis for 2-dimensional systolic and diastolic measures
Number of subjects: 125
Study 34932284 — intervention group
Group type: EXPERIMENTAL
Intervention: AboBoNT-A (Dysport) injections, mean doses 909-934 U between cycles 1 and 4
Number of subjects: 168
Study 34932284 — intervention group
Group type: EXPERIMENTAL
Intervention: OnaBoNT-A (Botox) injections
Number of subjects: 168
Study 34932284 — intervention group
Group type: EXPERIMENTAL
Intervention: IncoBoNT-A (Xeomin) injections
Number of subjects: 168
Study 34932394 — intervention group
Group type: EXPERIMENTAL
Intervention: Balstilimab (3 mg/kg every 2 weeks) and Zalifrelimab (1 mg/kg every 6 weeks)
Number of subjects: 155
Study 34932394 — intervention group
Group type: EXPERIMENTAL
Intervention: Balstilimab and Zalifrelimab
Number of subjects: 155
Study 34932560 — intervention group
Group type: EXPERIMENTAL
Intervention: mOPV2
Number of subjects: 0
Study 34932580 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary telemedicine intervention program
Number of subjects: 76
Study 34932580 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care only
Number of subjects: 76
Study 34932793 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab alone (cohort A)
Number of subjects: 46
Study 34932793 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus azacitidine (cohort B)
Number of subjects: 46
Study 34932793 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus azacitidine (cohort C)
Number of subjects: 46
Study 34932828 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 22
Study 34932828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34932836 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (haemoglobin threshold 7.0 g/dL to 8.0 g/dL)
Number of subjects: 21433
Study 34932836 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (haemoglobin threshold 9.0 g/dL to 10.0 g/dL)
Number of subjects: 21433
Study 34932836 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 21433
Study 34932836 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 21433
Study 34932887 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight-loss intervention
Number of subjects: 431
Study 34932887 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood physical abuse
Number of subjects: 431
Study 34932887 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse
Number of subjects: 431
Study 34932887 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge eating severity
Number of subjects: 431
Study 34932984 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR441255
Number of subjects: 0
Study 34932984 — intervention group
Group type: COMPARATOR
Intervention: Dual GLP-1/GCG receptor agonist
Number of subjects: 0
Study 34932991 — intervention group
Group type: COMPARATOR
Intervention: High-volume hospitals (>15 cases)
Number of subjects: 516
Study 34933328 — intervention group
Group type: EXPERIMENTAL
Intervention: Idecabtagene vicleucel (ide-cel)
Number of subjects: 128
Study 34933330 — intervention group
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Number of subjects: 27
Study 34933419 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmicroradical resection (0-mm margin)
Number of subjects: 276
Study 34933419 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection margin ≤1-mm without direct invasion
Number of subjects: 276
Study 34933419 — intervention group
Group type: COMPARATOR
Intervention: Control group (microradical resections)
Number of subjects: 276
Study 34933701 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan 0.5% followed by 70% alcoholic solution
Number of subjects: 0
Study 34933701 — intervention group
Group type: COMPARATOR
Intervention: Triclosan 0.5% by scrubbing
Number of subjects: 0
Study 34933824 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP measures collected at antimicrobial treatment start (V1), seven to 10 days later (V2), and two weeks after treatment end (V3).
Number of subjects: 982
Study 34933855 — intervention group
Group type: EXPERIMENTAL
Intervention: AcuPebble_SA100
Number of subjects: 150
Study 34933897 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA (Angiovue; Optovue, Fremont, California, USA)
Number of subjects: 88
Study 34933897 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA
Number of subjects: 88
Study 34933964 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels above median
Number of subjects: 269
Study 34933964 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 levels in the highest quartile
Number of subjects: 269
Study 34933964 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute and sustained elevation of IL-6 measured 4 months after STEMI
Number of subjects: 269
Study 34933965 — intervention group
Group type: EXPERIMENTAL
Intervention: sST2 concentrations at baseline
Number of subjects: 123
Study 34934034 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivascular endothelial growth factor therapy
Number of subjects: 2433
Study 34934447 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) followed by convalescent plasma (CVP) transfusion
Number of subjects: 38
Study 34934447 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment according to hospital protocols
Number of subjects: 38
Study 34934801 — intervention group
Group type: EXPERIMENTAL
Intervention: DRP3™ screen (a brief screening tool for H+D in dementia)
Number of subjects: 0
Study 34934801 — intervention group
Group type: EXPERIMENTAL
Intervention: DRP3™ screen
Number of subjects: 0
Study 34934864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (480 mg intravenously every 4 weeks) + Stereotactic Radiosurgery (SRS)
Number of subjects: 12
Study 34934978 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-carbohydrate (VLC) diet for 16 weeks
Number of subjects: 29
Study 34934987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (0.5 mg) twice weekly + placebo daily for 6 months
Number of subjects: 9
Study 34934987 — intervention group
Group type: COMPARATOR
Intervention: Norethindrone acetate (5 mg/day) + placebo twice weekly
Number of subjects: 9
Study 34935127 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (betamethasone or dexamethasone)
Number of subjects: 942
Study 34935127 — intervention group
Group type: COMPARATOR
Intervention: Usual care (placebo or no treatment)
Number of subjects: 942
Study 34935175 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV periodontitis
Number of subjects: 214
Study 34935175 — intervention group
Group type: COMPARATOR
Intervention: Stage I-III periodontitis
Number of subjects: 214
Study 34935409 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ischemic stroke/transient ischemic attack (AIS/TIA)
Number of subjects: 734
Study 34935409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage (ICH)
Number of subjects: 734
Study 34935412 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) volume measured with cardiac magnetic resonance
Number of subjects: 105
Study 34935483 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T therapy with ≥ grade 2 CRS
Number of subjects: 22
Study 34935483 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T therapy
Number of subjects: 22
Study 34935483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging hematopoietic stem cell transplantation
Number of subjects: 22
Study 34935687 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL 4% gelatin intravenous boluses (five sequential boluses)
Number of subjects: 47
Study 34935687 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mL fluid challenge (FC)
Number of subjects: 47
Study 34935687 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid administration
Number of subjects: 47
Study 34935687 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Ea
Number of subjects: 47
Study 34935913 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 mRNA vaccine (two doses of Pfizer-BioNTech)
Number of subjects: 129
Study 34936055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral BI 425809 25 mg
Number of subjects: 6
Study 34936055 — intervention group
Group type: COMPARATOR
Intervention: IV microtracer infusion
Number of subjects: 6
Study 34936055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-form BI 425809
Number of subjects: 6
Study 34936689 — intervention group
Group type: COMPARATOR
Intervention: Multimodal assessment tools (symptom, cognitive, visual, motor) using digital methods
Number of subjects: 200
Study 34936697 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus lenalidomide (GALEN combination)
Number of subjects: 100
Study 34936849 — intervention group
Group type: EXPERIMENTAL
Intervention: Elexacaftor/Tezacaftor/Ivacaftor Therapy
Number of subjects: 0
Study 34937189 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-Tazobactam continuous infusion
Number of subjects: 26
Study 34937189 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-Tazobactam intermittent bolus, extended infusion, and continuous infusion methods
Number of subjects: 26
Study 34937556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 146
Study 34937556 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 146
Study 34937583 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume intake
Number of subjects: 2247
Study 34937583 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2247
Study 34937709 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound (LUS)
Number of subjects: 235
Study 34937720 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified treatment based on prognostic factors
Number of subjects: 1000
Study 34937722 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention using a clinical decision support system based on behavioural economic and user-centred design principles.
Number of subjects: 184
Study 34937722 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 184
Study 34937724 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up care every 4 weeks in long interdialytic interval (LIDI) for pre-dialysis and post-dialysis serum potassium measurements.
Number of subjects: 600
Study 34937724 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visit in the short interdialytic interval (SIDI) during the first week.
Number of subjects: 600
Study 34937781 — intervention group
Group type: EXPERIMENTAL
Intervention: High CSF Aβ
Number of subjects: 0
Study 34937781 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher CSF Aβ
Number of subjects: 0
Study 34937789 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Erasmus GBS Outcome Score (mEGOS) at entry
Number of subjects: 1500
Study 34937789 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Erasmus GBS Outcome Score (mEGOS) at week 1
Number of subjects: 1500
Study 34937789 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalibrated mEGOS for Europe/North America (mEGOS-Eu/NA)
Number of subjects: 1500
Study 34937789 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual predictive factors of mEGOS
Number of subjects: 1500
Study 34937871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO MONO)
Number of subjects: 32
Study 34937871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (COMBO)
Number of subjects: 32
Study 34938226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness program
Number of subjects: 0
Study 34938226 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mindfulness program)
Number of subjects: 0
Study 34938285 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H1N1pdm09 vaccine (2009)
Number of subjects: 55
Study 34938285 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal vaccination (2010/11-2013/14)
Number of subjects: 55
Study 34938285 — intervention group
Group type: EXPERIMENTAL
Intervention: Current vaccination (2013/14)
Number of subjects: 55
Study 34938285 — intervention group
Group type: EXPERIMENTAL
Intervention: Two- and three-year gap before vaccination (2013/14)
Number of subjects: 55
Study 34938664 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax 800 mg/day
Number of subjects: 17
Study 34938699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention details are not available
Number of subjects: 0
Study 34938780 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-Based Exercise and Cognitive Training
Number of subjects: 0
Study 34938780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34938862 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic endonasal transsphenoidal surgery
Number of subjects: 44
Study 34938959 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 309
Study 34939008 — intervention group
Group type: EXPERIMENTAL
Intervention: HDx therapy (medium cut-off dialyzer) for 12 weeks after a 2-week baseline observation period of conventional high-flux HD
Number of subjects: 28
Study 34939008 — intervention group
Group type: EXPERIMENTAL
Intervention: HDx therapy
Number of subjects: 28
Study 34939008 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic PROM assessment
Number of subjects: 28
Study 34939013 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine n-3 PUFA (2.6 g daily for 44 weeks)
Number of subjects: 132
Study 34939013 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo)
Number of subjects: 132
Study 34939109 — intervention group
Group type: COMPARATOR
Intervention: No ACL reconstruction (no ACLR)
Number of subjects: 275
Study 34939109 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ACLR
Number of subjects: 275
Study 34939109 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline general self-efficacy
Number of subjects: 275
Study 34939109 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 275
Study 34939109 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline knee function
Number of subjects: 275
Study 34939173 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET/CT imaging
Number of subjects: 104
Study 34939444 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice combined with patient education (PE) for at-home practice, 12 weeks duration, including two 6-week periods: P1 with one 90-minutes supervised yoga-PE session/week and 15-minutes daily at-home yoga, P2 with daily autonomous at-home yoga sessions.
Number of subjects: 24
Study 34939444 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga practice combined with patient education (PE) for at-home practice
Number of subjects: 24
Study 34939972 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimuli-based quantitative sensory testing (QST)
Number of subjects: 72
Study 34939987 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy initiation among AYALWH older than 10 years
Number of subjects: 5316
Study 34939987 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilities with youth-friendly services (YFS) and trained providers
Number of subjects: 5316
Study 34939987 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall viral suppression among AYALWH
Number of subjects: 5316
Study 34941047 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with anlotinib, irinotecan, and vincristine
Number of subjects: 35
Study 34941067 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin 1.88 to 3.75 mg subcutaneously once every 4 weeks for 96 weeks
Number of subjects: 307
Study 34941429 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulation, details on dosage and duration not available
Number of subjects: 0
Study 34941552 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Research Information System (CRIS)
Number of subjects: 0
Study 34941904 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (TM)
Number of subjects: 89
Study 34941904 — intervention group
Group type: COMPARATOR
Intervention: Conventional monitoring (CM)
Number of subjects: 89
Study 34941929 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 88
Study 34941929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 34941996 — intervention group
Group type: EXPERIMENTAL
Intervention: Glofitamab (5 µg-25 mg) after single-dose obinutuzumab pretreatment (1000 mg) 7 days prior
Number of subjects: 0
Study 34941996 — intervention group
Group type: EXPERIMENTAL
Intervention: Glofitamab (5 µg-25 mg)
Number of subjects: 0
Study 34942053 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 1703
Study 34942138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate (2.5-9.0 g/night)
Number of subjects: 154
Study 34942138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 34942138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-sodium oxybate
Number of subjects: 154
Study 34942337 — intervention group
Group type: EXPERIMENTAL
Intervention: US-LRA group
Number of subjects: 90
Study 34942337 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 34942516 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation (target network: DMN in AD, SN in bvFTD)
Number of subjects: 45
Study 34942516 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation (target network: SN in AD, DMN in bvFTD)
Number of subjects: 45
Study 34942516 — intervention group
Group type: COMPARATOR
Intervention: Functional connectivity
Number of subjects: 45
Study 34942516 — intervention group
Group type: COMPARATOR
Intervention: Perfusion measures
Number of subjects: 45
Study 34942516 — intervention group
Group type: COMPARATOR
Intervention: Interaction between DMN and SN functional connectivity changes
Number of subjects: 45
Study 34944886 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived beta glucan (BG) combined with anti-GD2 murine monoclonal antibody 3F8, intravenous 3F8 at a fixed dose of 10 mg/m².
Number of subjects: 0
Study 34945081 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychotherapy (STP)
Number of subjects: 0
Study 34945145 — intervention group
Group type: EXPERIMENTAL
Intervention: @ctivehip (tele-rehabilitation program)
Number of subjects: 21
Study 34945205 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution anorectal manometry
Number of subjects: 16